Biology of Anti-Angiogenic Therapy¨CInduced Thrombotic Microangiopathy

详细信息    查看全文

• 作者：Vera Eremina ; MD ; PhD^?/sup> ; Susan E. Quaggin ; MD^?/sup> ; ^&dagger ; ; ^&Dagger ; ; ^{quaggin@lunenfeld.ca}
• 关键词：Anti-VEGF therapy ; TMA ; glomerulus ; endothelial cells
• 刊名：Seminars in Nephrology
• 出版年：2010
• 出版时间：November 2010
• 年：2010
• 卷：30
• 期：6
• 页码：582-590
• 全文大小：1652 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferencesersion=""1.0"" encoding=""UTF-8""?>

Summary

Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.